Use of potassium channel blockers to treat cerebral palsy

摘要

Provided is the use of 4-aminopyridine, 3-aminopyridine or 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof in the manufacture of a composition for treating a sign or symptom of cerebral palsy (”CP”) or an impairment or alteration consequent to CP in a patient with CP, and wherein the sign or symptom of CP or the impairment or alteration consequent to CP is not an impairment in mental status.